BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its ...

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...

Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, ...

Hormone therapy can affect collagen, hydration, and breakouts during menopause. Dermatologists explain the real skin benefits ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Elfabrio (R) (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed diagnosis of Fabry disease (deficiency of ...

UC San Diego researchers uncover enzyme behind cancer genome chaos, pointing to potential therapies for aggressive tumors.

University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which ...

UC San Diego scientists discover enzyme responsible for scrambling cancer genomes; results could enable new treatments for ...